Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

9.8%

4 terminated out of 41 trials

Success Rate

89.2%

+2.7% vs benchmark

Late-Stage Pipeline

49%

20 trials in Phase 3/4

Results Transparency

27%

9 of 33 completed with results

Key Signals

9 with results89% success

Data Visualizations

Phase Distribution

37Total
Not Applicable (8)
P 1 (1)
P 2 (8)
P 3 (16)
P 4 (4)

Trial Status

Completed33
Terminated4
Unknown2
Suspended1
Not Yet Recruiting1

Trial Success Rate

89.2%

Benchmark: 86.5%

Based on 33 completed trials

Clinical Trials (41)

Showing 20 of 20 trials
NCT04943068Phase 3CompletedPrimary

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

NCT06082817Phase 2Not Yet RecruitingPrimary

An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD

NCT04179734Phase 4CompletedPrimary

Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

NCT02770768Not ApplicableTerminatedPrimary

Effects of Flibanserin on the Pre- and Post-menopausal Female Brain

NCT04824820Not ApplicableCompleted

Improving Female Sexual Wellness

NCT03780751Not ApplicableCompletedPrimary

Waitlist Controlled Comparison of Cognitive-behavioral vs. Mindfulness-based Online-treatments for Women With Low Sexual Desire

NCT03232801Not ApplicableCompletedPrimary

A Mindfulness-based Intervention for Older Women With Low Sexual Desire

NCT02430987Not ApplicableCompleted

Low Sexual Desire and Metabolic Syndrome

NCT02714049Phase 4TerminatedPrimary

Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy

NCT00612742Phase 3CompletedPrimary

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT03287232Phase 3CompletedPrimary

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT02333071Phase 3CompletedPrimary

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT02338960Phase 3CompletedPrimary

2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT04336891CompletedPrimary

Effect of Testosterone Treatment on Clitoral Arteries' Hemodynamic Parameters.

NCT02859285Not ApplicableCompletedPrimary

A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women

NCT03463707Phase 3CompletedPrimary

BP101 for Adults With Female Sexual Dysfunction

NCT01208038Phase 4CompletedPrimary

Testosterone Patch's Effects on the Cardiovascular System and Libido

NCT02593396Phase 2Completed

Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men

NCT02968342Phase 4Unknown

Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women

NCT02419209Phase 2CompletedPrimary

The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause

Scroll to load more

Research Network

Activity Timeline